Strategic partnerships DSL is actively presenting with Immundiagnostik at major conferences (DDW 2026) to showcase fecal gluten peptide testing, signaling openness to co-branded offerings and distributor-style collaborations that can expand market reach.

Clinical breadth With over 500 validated assays and leadership spanning both lab science and clinical health, there is a strong position to cross-sell comprehensive diagnostic panels to multi-disciplinary practices seeking integrated testing solutions.

Celiac & gluten testing Recent emphasis on fecal gluten peptide testing for monitoring gluten-free diet adherence presents an opportunity to target gastroenterology clinics, dietitian networks, and gluten-related disorder programs.

COVID-era capabilities Early development of COVID-19 tests demonstrates DSL’s R&D agility and manufacturing capacity, suggesting potential for rapid development and deployment of new assays in response to emerging health threats.

Scale and growth Revenue scope (estimated $50M-$100M) alongside a mid-sized team indicates a scalable operation with potential for enterprise partnerships, contract manufacturing, or licensed assay commercialization with health systems seeking reliable external labs.